Replies to post #95 on Equity Field Notes from temporal sources

[DanWebzster]

ATRS 9/29/18 is the PDUFA date for its subcutaneous testosterone treatment

Royalty revenues from AMAG's auto-injectable Makena should increase for mush of 2018.

Otrexup and their auto-injectable migraine treatment continue to grow

ANDAs for 3 TEVA-partnered generics have been submitted including an Epipen product that is a potential $500mn-plus opty.

In their latest reported Q, net loss fell to $3.7mn with cash equaling $31.6mn

* consider a run-up strategy after June earnings release.

[DanWebzster]

BDSI has benefited from the growing awareness of the Sackler Opioid Crisis

Q1/18 YoY growth = 19%

Belbuca is their highest growth product. It is a Schedule III opioid that doctors now find more acceptable to prescribe than Schedule II opioids

BDSI is still burning cash; but, the runway could extend thru 2020.